Shire Says Genzyme Can't Prove False Bone Drug Claims

Law360, New York (August 22, 2012, 2:49 PM EDT) -- A Shire PLC unit asked a Massachusetts federal court on Tuesday to dismiss Genzyme Corp.’s complaint alleging Shire misled consumers by advertising its bone disease drug as superior to Genzyme’s Cerezyme, saying the plaintiff was wrongly using the suit to win back market share.

In its motion to dismiss, Shire Human Genetic Therapies Inc. said a June 28 press release publicizing the results of a Shire study with which Genzyme had taken issue was accurate. The release was based on genuine scientific data and was not...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.